Drug Type Trispecific antibody  | 
Synonyms MB 7, MB7  | 
Target  | 
Action inhibitors  | 
Mechanism IL-21 inhibitors(Interleukin-21 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors)  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhaseDiscovery  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Discovery | South Korea   | 17 Apr 2024 | 






